Owlet withdrew its 2026 outlook following a voluntary camera safety update.
Paying Owlet360 subscribers reached 142,000 in the third quarter of 2026.
Amazon removed non-cleared competing baby monitors from its site in September.
On its third-quarter 2026 earnings call, held on Nov. 13, 2026, Owlet (NYSE:OWLT) announced a voluntary camera safety update and withdrew its full-year financial outlook. The safety action creates immediate revenue cuts, but long-term value hinges on core product demand and subscription growth.
Three takeaways from the call stand out for long-term investors.
Management pulled full-year financial guidance after initiating a voluntary safety update for its camera cord attachment, which requires accepting product returns from retail partners and shipping replacement parts.
We estimate retailer returns of $9 million-$12 million, which will be recorded as a reduction of revenue in the fourth quarter.
-- Amanda Twede Crawford, Chief Financial Officer
The Owlet360 subscription service reached 142,000 paying users, providing recurring software revenue that expands customer lifetime value beyond initial hardware purchases.
Annual signups nearly tripled quarter-over-quarter, and annual plans now make up 13% of subscribers, up from 8% in June.
-- Kurt Workman, President, Chief Executive Officer, and Co-Founder
By late September, Amazon removed competitors that lacked Food and Drug Administration (FDA) clearance, solidifying Owlet's regulatory position in vital-signs tracking.
As a result, Owlet Dream Sock is now the only baby monitor on Amazon that tracks instant vital signs, giving us a durable long-term advantage.
-- Amanda Twede Crawford, Chief Financial Officer
Near-term revenue faces headwinds from camera cord replacements, but demand for the core Dream Sock monitor remains unaffected. Management is relying on expanding software features, expanding international distribution, and pricing discipline to protect long-term margins.
We anticipate some near-term disruption during the safety update process, but it's the right thing to do for families to trust us and for the long-term business.
-- Kurt Workman, President, Chief Executive Officer, and Co-Founder
Owlet retains a distinct competitive position as the sole infant health monitor with FDA clearance.
Our commitment to our mission is stronger than ever, and we're confident in the opportunity ahead.
-- Kurt Workman, President, Chief Executive Officer, and Co-Founder
Before you buy stock in Owlet, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Owlet wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $335,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,000,640!*
Now, it’s worth noting Stock Advisor’s total average return is 823% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 16, 2026.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.